Cubist Pharmaceuticals (CBST) Tops Q3 EPS Views
More News related to CBST
- The Boston Globe names Cubist to Globe 100's Top Places to Work '09
- Cubist Pharmaceuticals to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Oppenheimer Upgrades Cubist Pharmaceuticals (CBST) to Perform
- Hydra Biosciences and Cubist Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management
- Cubist Pharmaceuticals (CBST) Tops Q3 EPS Views
More News related to Earnings
- After-Hours Movers 11/23: CNO, RMBS, NUAN, ADI Higher; HAYN, DY, DBLE, CISG, IPAR, KWR Lower
- Trading Radar for 11/24: Heinz (HNZ), Dollar Tree (DLTR), Eaton Vance (EV), Hormel Foods (HRL), J. Crew (JCG) Report
- Afternoon ETF Check: GDX, KBE Higher; UUP Lower
- Unusual 11 Mid-Day Movers 11/23: ABIO, SEED, FNET, CDTI Higher; NYNY, GGR, TTIL, PEET Lower
- Best of the Web 11/23: Suicides On the Rise, U.S. Debt Service Could Top $700B, Really? An Insider Trading Beauty Queen
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) reports Q3 EPS of $0.42, or $0.65 non-GAAP, 9 better than the analyst estimate of $0.33. Revenue rose 28% to $143.5 million, which compares to the estimate of $142.12 million.
Related Categories
EarningsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
